𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunologic effector mechanisms in hepatitis B-negative chronic active hepatitis

✍ Scribed by Klingenstein, R. James ;Wands, Jack R.

Publisher
Springer
Year
1980
Tongue
English
Weight
950 KB
Volume
3
Category
Article
ISSN
0344-4325

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B e antigen–negative chronic h
Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong
✍ Henry L. Y. Chan; Nancy W. Y. Leung; Munira Hussain; May L. Wong; Anna S. F. Lok 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

Hepatitis B e antigen-negative chronic hepatitis B (eϪCHB) has been reported in Asia but its prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of eϪCHB in Hong Kong and the frequency of precore and core promoter mutations in these

Hepatitis B and D genomes in hepatitis B
Hepatitis B and D genomes in hepatitis B surface antigen negative patients with chronic hepatitis C
✍ Sara González; Sonia Navas; Antonio Madejón; Javier Bartolomé; Inmaculada Castil 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 607 KB

## Abstract Hepatitis B and hepatitis D viral genomes were tested by nested polymerase chain reaction in the serum and liver of 69 hepatitis B surface antigen (HBsAg) negative, anti‐hepatitis C virus (HCV) positive patients (47 with HCV RNA and 22 without HCV RNA). Serum hepatitis B virus (HBV) DNA

Serum hepatitis B virus-DNA cutoff level
Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen–negative chronic hepatitis B virus infection
✍ George V. Papatheodoridis; Emanuel K. Manesis; Spilios Manolakopoulos; Athanasio 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004;40:255-260. 6. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429-438. 7. Magnes

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60